Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00612352
Other study ID # 0304025194
Secondary ID VA Alcohol Resea
Status Completed
Phase N/A
First received
Last updated
Start date March 2001
Est. completion date June 2015

Study information

Verified date October 2021
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The proposed study is the first to explore the contribution of brain glutamate systems, a major target of ethanol in the brain, to the vulnerability to develop alcoholism. This study may lead to an enhanced understanding of the underlying neurobiological mechanism in high risk individuals that may lead to the transition from moderate to excessive use of alcohol.


Description:

Males and females with a paternal family history of alcoholism have a high risk for developing alcoholism. These individuals have been shown to have decreased dysphoric responses to alcohol self-administration that may promote the excessive use of alcohol. Ethanol has been shown to be an antagonist at the N-methyl-D-aspartate (NMDA) glutamate receptor. We have recently shown that sober alcoholics have decreased dysphoric response to the NMDA antagonist, ketamine. We propose to test the hypothesis that this characteristic exists as a vulnerability factor in those individuals susceptible to develop alcoholism. Specifically, the objective is to determine whether individuals with a family history positive (FHP) for alcoholism will experience less dysphoric, anxiogenic, and psychotogenic effects to alcohol infusion when compared to family history negative (FHN) control subjects. Male and female subjects, FHP (biological father and one other first degree relative) between the ages of 21-30, and matched controls (FHN) will complete 3 test days in a randomized balanced order under double-blind conditions. Test days will involve administration of placebo or one of two ethanol doses (target BrAc=40mg%, or target BrAc=100mg%) intravenously for 20 minutes, until the target BrAc is achieved. Once BrAc is achieved (40mg% or 100mg%) it will be maintained using a clamp procedure for over 60 minutes. Outcome measures include the Positive and Negative Symptom Scale, visual analog scales of mood state, (i.e. anxiety) and the Clinician-Administered Dissociative States Scale (CADSS) to measure perceptual responses to alcohol. Secondary measures include visual analog scales for high, similarity to ethanol, Mini Mental Status Examination (MMSE), Placement of electrodes, Biphasic Alcohol Effects Scale, Hopkins Verbal Learning, and number of drinks scale, aspects of craving for alcohol and tests of cognitive impairment.


Recruitment information / eligibility

Status Completed
Enrollment 180
Est. completion date June 2015
Est. primary completion date June 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 30 Years
Eligibility Inclusion Criteria: 1. Male and female between the ages of 21 and 30 years; 2. medically and neurologically healthy on the basis of history, physical examination, EKG, Screening laboratories absence of current and/or past substance abuse on the basis of history and urine toxicology and breath alcohol levels at screening and on each test day. For Family History Positive (FHP) Subjects: 1) Biological father and another first or second-degree biological relative with history of alcoholism by Family History Assessment Module (FHAM) developed by COGA. Exclusion Criteria: 1. DSM-IV psychiatric and substance abuse (excluding alcohol abuse) diagnosis by history on psychiatric evaluation that includes a structured diagnostic interview (Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)-IV Axis I Disorders (SCID)) 2. Subjects who meet criteria for alcohol abuse and express an interest in stopping alcohol use and/or express an interest in treatment or are currently enrolled in treatment for alcoholism, or have sought treatment in the last 6 months. 3. history of counseling or psychotherapy; except family therapy centered around another family member 4. extended unwillingness to remain alcohol-free for 48 hours prior to test days; 5. for women: positive pregnancy test at screening or intention to engage in unprotected sex during the study 6. alcohol naïve 7. Adoptee and no contact with family members.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ethanol High Dose, Ethanol Low Dose, and Placebo
Three test days will involve administration of placebo, ethanol high dose (BrAc=100mg%) or ethanol low dose (BrAc=40mg%)intravenously for approximately 20 minutes, until the target BrAc is achieved. Once BrAc is achieved (40mg% or 100mg%) it will be maintained using a clamp procedure for 60 minutes.

Locations

Country Name City State
United States VA Connecticut Healthcare System West Haven Connecticut

Sponsors (3)

Lead Sponsor Collaborator
Yale University National Institute on Alcohol Abuse and Alcoholism (NIAAA), VA Connecticut Healthcare System

Country where clinical trial is conducted

United States, 

References & Publications (2)

Perrino AC Jr, Ralevski E, Acampora G, Edgecombe J, Limoncelli D, Petrakis IL. Ethanol and pain sensitivity: effects in healthy subjects using an acute pain paradigm. Alcohol Clin Exp Res. 2008 Jun;32(6):952-8. doi: 10.1111/j.1530-0277.2008.00653.x. Epub — View Citation

Ralevski E, Perrino A, Acampora G, Koretski J, Limoncelli D, Petrakis I. Analgesic effects of ethanol are influenced by family history of alcoholism and neuroticism. Alcohol Clin Exp Res. 2010 Aug;34(8):1433-41. doi: 10.1111/j.1530-0277.2010.01228.x. Epub — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Drinks Felt Consumed at Baseline The Number of Drinks Scale asks Subjects to report on the number of alcoholic drinks they felt they had consumed. Baseline
Primary Number of Drinks Felt Consumed at 10 Minutes The Number of Drinks Scale asks Subjects to report on the number of alcoholic drinks they felt they had consumed. 10 minutes
Primary Number of Drinks Felt Consumed at 30 Minutes The Number of Drinks Scale asks Subjects to report on the number of alcoholic drinks they felt they had consumed. 30 minutes
Primary Number of Drinks Felt Consumed at 110 Minutes The Number of Drinks Scale asks Subjects to report on the number of alcoholic drinks they felt they had consumed. 110 minutes
Primary Number of Drinks Felt Consumed at 140 Minutes The Number of Drinks Scale asks Subjects to report on the number of alcoholic drinks they felt they had consumed. 140 minutes
Primary Number of Drinks Felt Consumed at 170 Minutes The Number of Drinks Scale asks Subjects to report on the number of alcoholic drinks they felt they had consumed. 170 minutes
Primary Number of Drinks Felt Consumed at 230 Minutes The Number of Drinks Scale asks Subjects to report on the number of alcoholic drinks they felt they had consumed. 230 minutes
Primary Visual Analog Scale of Similarity to Alcohol - Baseline Visual Analog Scale of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol - 7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol Baseline
Primary Visual Analog Scale of Similarity to Alcohol -10 Minutes Visual Analog Scale of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol - 7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol 10 minutes
Primary Visual Analog Scale of Similarity to Alcohol - 30 Minutes Visual Analog Scale of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol - 7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol 30 minutes
Primary Visual Analog Scale of Similarity to Alcohol - 60 Minutes Visual Analog Scale of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol - 7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol 60 minutes
Primary Visual Analog Scale of Similarity to Alcohol - 110 Minutes Visual Analog Scale of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol - 7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol 110 minutes
Primary Visual Analog Scale of Similarity to Alcohol - 140 Minutes Visual Analog Scale of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol - 7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol 140 minutes
Primary Visual Analog Scale of Similarity to Alcohol - 170 Minutes Visual Analog Scale of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol - 7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol 170 minutes
Primary Visual Analog Scale of Similarity to Alcohol - 230 Minutes Visual Analog Scale of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol - 7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol 230 minutes
Secondary Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative Baseline Self-report rating scale used to measure sedative effects (0 not at all sedated - 70 extremely sedated) Baseline
Secondary Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative - 10 Minutes Self-report rating scale used to measure sedative effects (0 not at all sedated - 70 extremely sedated) 10 minutes
Secondary Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative - 30 Minutes Self-report rating scale used to measure sedative effects (0 not at all sedated - 70 extremely sedated) 30 minutes
Secondary Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative - 60 Minutes Self-report rating scale used to measure sedative effects (0 not at all sedated - 70 extremely sedated) 60 minutes
Secondary Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative - 110 Minutes Self-report rating scale used to measure sedative effects (0 not at all sedated - 70 extremely sedated) 110 minutes
Secondary Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative - 140 Minutes Self-report rating scale used to measure sedative effects (0 not at all sedated - 70 extremely sedated) 140 minutes
Secondary Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative - 170 Minutes Self-report rating scale used to measure sedative effects (0 not at all sedated - 70 extremely sedated) 170 minutes
Secondary Biphasic Alcohol Effects Scale (BAES) - Subscale Sedative - 230 Minutes Self-report rating scale used to measure sedative effects (0 not at all sedated - 70 extremely sedated) 230 minutes
Secondary Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant - Baseline Self-report rating scale used to measure stimulant effects (0 not at all stimulated - 70 extremely stimulated) Baseline
Secondary Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant - 10 Minutes Self-report rating scale used to measure stimulant effects (0 not at all stimulated - 70 extremely stimulated) 10 minutes
Secondary Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant - 30 Minutes Self-report rating scale used to measure stimulant effects (0 not at all stimulated - 70 extremely stimulated) 30 minutes
Secondary Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant - 60 Minutes Self-report rating scale used to measure stimulant effects (0 not at all stimulated - 70 extremely stimulated) 60 minutes
Secondary Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant - 110 Minutes Self-report rating scale used to measure stimulant effects (0 not at all stimulated - 70 extremely stimulated) 110 minutes
Secondary Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant - 140 Minutes Self-report rating scale used to measure stimulant effects (0 not at all stimulated - 70 extremely stimulated) 140 minutes
Secondary Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant - 170 Minutes Self-report rating scale used to measure stimulant effects (0 not at all stimulated - 70 extremely stimulated) 170 minutes
Secondary Biphasic Alcohol Effects Scale (BAES) - Subscale Stimulant - 240 Minutes Self-report rating scale used to measure stimulant effects (0 not at all stimulated - 70 extremely stimulated) 240 minutes
Secondary Visual Analog Scale (VAS) HIGH - Baseline visual analog scale (VAS): self-report scale used to measure high (0 not at all High - 7 extremely High) Baseline
Secondary Visual Analog Scale (VAS) HIGH - 10 Minutes visual analog scale (VAS): self-report scale used to measure high (0 not at all High - 7 extremely High) 10 minutes
Secondary Visual Analog Scale (VAS) HIGH - 30 Minutes visual analog scale (VAS): self-report scale used to measure high (0 not at all High - 7 extremely High) 30 minutes
Secondary Visual Analog Scale (VAS) HIGH - 60 Minutes visual analog scale (VAS): self-report scale used to measure high (0 not at all High - 7 extremely High) 60 minutes
Secondary Visual Analog Scale (VAS) HIGH - 110 Minutes visual analog scale (VAS): self-report scale used to measure high (0 not at all High - 7 extremely High) 110 minutes
Secondary Visual Analog Scale (VAS) HIGH - 140 Minutes visual analog scale (VAS): self-report scale used to measure high (0 not at all High - 7 extremely High) 140 minutes
Secondary Visual Analog Scale (VAS) HIGH - 170 Minutes visual analog scale (VAS): self-report scale used to measure high (0 not at all High - 7 extremely High) 170 minutes
Secondary Visual Analog Scale (VAS) HIGH - 240 Minutes visual analog scale (VAS): self-report scale used to measure high (0 not at all High - 7 extremely High) 240 minutes
Secondary Visual Analog Scale (VAS) Drowsy - Baseline visual analog scale (VAS): self-report scale used to measure Drowsy (0 not at all drowsy - 7 extremely drowsy) Baseline
Secondary Visual Analog Scale (VAS) Drowsy - 10 Minutes visual analog scale (VAS): self-report scale used to measure Drowsy (0 not at all drowsy - 7 extremely drowsy) 10 minutes
Secondary Visual Analog Scale (VAS) Drowsy - 30 Minutes visual analog scale (VAS): self-report scale used to measure Drowsy (0 not at all drowsy - 7 extremely drowsy) 30 minutes
Secondary Visual Analog Scale (VAS) Drowsy - 60 Minutes visual analog scale (VAS): self-report scale used to measure Drowsy (0 not at all drowsy - 7 extremely drowsy) 60 minutes
Secondary Visual Analog Scale (VAS) Drowsy - 110 Minutes visual analog scale (VAS): self-report scale used to measure Drowsy (0 not at all drowsy - 7 extremely drowsy) 110 minutes
Secondary Visual Analog Scale (VAS) Drowsy - 140 Minutes visual analog scale (VAS): self-report scale used to measure Drowsy (0 not at all drowsy - 7 extremely drowsy) 140 minutes
Secondary Visual Analog Scale (VAS) Drowsy - 170 Minutes visual analog scale (VAS): self-report scale used to measure Drowsy (0 not at all drowsy - 7 extremely drowsy) 170 minutes
Secondary Visual Analog Scale (VAS) Drowsy - 230 Minutes visual analog scale (VAS): self-report scale used to measure Drowsy (0 not at all drowsy - 7 extremely drowsy) 230 minutes
Secondary Hopkins Verbal Learning Task - Immediate Recall - Trial 1 Hopkins Verbal Learning Task (HVLT) - measures verbal memory and hippocampus function. (Three immediate recall trials) (0 no words recalled - 12 all words recalled) 30 minutes - Trial 1
Secondary Hopkins Verbal Learning Task - Immediate Recall - Trial 2 Hopkins Verbal Learning Task (HVLT) - measures verbal memory and hippocampus function. (Three immediate recall trials) (0 no words recalled - 12 all words recalled) 30 minutes - Trial 2
Secondary Hopkins Verbal Learning Task - Immediate Recall - Trial 3 Hopkins Verbal Learning Task (HVLT) - measures verbal memory and hippocampus function. (Three immediate recall trials) (0 no words recalled - 12 all words recalled) 30 minutes - Trial 3
Secondary Hopkins Verbal Learning Task - Delay Recall Hopkins Verbal Learning Task (HVLT) - measures verbal memory and hippocampus function. (Delay Recall: 30 minutes after Trials 1-3 were given) (0 no words recalled - 12 all words recalled) 60 minutes
Secondary Pegboard Task - Baseline (Dominant Hand) The pegboard task is a measure of coordination that measures reaction time; how long a subject takes to insert pegs into a pegboard puzzle, first using their dominant hand then using their non-dominant hand. A quicker time indicates greater coordination. Scores are timed in seconds Baseline
Secondary Pegboard Task - 30 Minutes (Dominant Hand) The pegboard task is a measure of coordination that measures reaction time; how long a subject takes to insert pegs into a pegboard puzzle, first using their dominant hand then using their non-dominant hand. A quicker time indicates greater coordination. Scores are timed in seconds. 30 minutes
Secondary Pegboard Task - Baseline (Non-Dominant Hand) The pegboard task is a measure of coordination that measures reaction time; how long a subject takes to insert pegs into a pegboard puzzle, first using their dominant hand then using their non-dominant hand. A quicker time indicates greater coordination. Scores are timed in seconds. Baseline
Secondary Pegboard Task - 30 Minuites (Non-Dominant Hand) The pegboard task is a measure of coordination that measures reaction time; how long a subject takes to insert pegs into a pegboard puzzle, first using their dominant hand then using their non-dominant hand. A quicker time indicates greater coordination. Scores are timed in seconds. 30 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT05054738 - CRP and S&A for Inpatient Veterans N/A
Completed NCT02233738 - Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services N/A
Completed NCT05877807 - Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
Completed NCT00000437 - Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone) Phase 4
Completed NCT00536146 - The Stress-Hormone System in Alcohol-Dependent Subjects N/A
Terminated NCT00890149 - Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults Phase 2
Completed NCT02179749 - Mifepristone Treatment of Alcohol Use Disorder Phase 2
Completed NCT02939352 - The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues Early Phase 1
Completed NCT01553136 - Varenicline Treatment of Alcohol Dependence in Smokers Phase 2
Terminated NCT01408641 - Topiramate for Alcohol Use in Posttraumatic Stress Disorder N/A
Completed NCT01389297 - Overcoming Addictions: A Randomized Clinical Trial of a Web Application Based on SMART Recovery N/A
Completed NCT00768508 - Combined Pharmacotherapies for Alcoholism Phase 3
Completed NCT01113164 - Matching Genotypes and Serotonergic Medications for Alcoholism Phase 1
Completed NCT01760785 - Valproate for Mood Swings and Alcohol Use Following Head Injury N/A
Completed NCT00127231 - Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women N/A
Terminated NCT02842528 - Cognitive Vulnerability Factors in Alcohol-dependence N/A
Completed NCT00367575 - An Internet-based Intervention for Problem Drinking N/A
Completed NCT00583440 - 12-step Facilitation for the Dually Diagnosed Phase 1/Phase 2
Completed NCT00223639 - New Medications to Treat Alcohol Dependence Phase 2
Completed NCT00167687 - Prazosin Alcohol Dependence IVR Study Phase 4